AbbVie joined the 10 %
price - hike pledge on Wednesday, following Allergan and Novo Nordisk, as the
drug pricing debate sent biopharma shares reeling once
again.
The UK's National Institute for Health and Clinical Excellence (NICE), which provides guidance on use of new
drugs and medical technologies, showed yet
again that
price is a key consideration, backing an Amgen
drug only after being offered rebates by the manufacturer.